GlycoNex (TWO:4168) — Market Cap & Net Worth
Market Cap & Net Worth: GlycoNex (4168)
GlycoNex (TWO:4168) has a market capitalization of $75.16 Million (NT$2.39 Billion) as of September 18, 2026. Listed on the TWO stock exchange, this Taiwan-based company holds position #20399 globally and #1191 in its home market, demonstrating a -1.37% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GlycoNex's stock price NT$21.55 by its total outstanding shares 110708133 (110.71 Million). Also see 4168 total asset value for a full breakdown of the balance sheet.
GlycoNex Market Cap History: 2015 to 2026
GlycoNex's market capitalization history from 2015 to 2026. Data shows change from $188.67 Million to $75.16 Million (-8.49% CAGR). Also see 4168 cash flow metrics for how efficiently the company converts equity into cash flow.
GlycoNex Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GlycoNex's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check GlycoNex (4168) stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
5.94x
GlycoNex's market cap is 5.94 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $79.69 Million | $634.00K | -$144.59 Million | 125.69x | N/A |
| 2018 | $80.56 Million | $926.00K | -$316.94 Million | 87.00x | N/A |
| 2019 | $70.98 Million | $734.00K | -$247.23 Million | 96.70x | N/A |
| 2020 | $100.10 Million | $451.00K | -$162.73 Million | 221.96x | N/A |
| 2021 | $103.24 Million | $5.47 Million | -$172.49 Million | 18.86x | N/A |
| 2022 | $106.21 Million | $30.09 Million | -$219.82 Million | 3.53x | N/A |
| 2023 | $103.77 Million | $2.54 Million | -$178.36 Million | 40.82x | N/A |
| 2024 | $87.37 Million | $14.70 Million | -$229.71 Million | 5.94x | N/A |
Competitor Companies of 4168 by Market Capitalization
Companies near GlycoNex in the global market cap rankings as of September 18, 2026. Review GlycoNex tangible book value ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to GlycoNex by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #187 globally with a market cap of $130.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.34 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.87 Billion USD ( AU$84.62 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #505 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #187 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.09 Billion | $513.26 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.34 Billion | $774.61 |
| #457 | CSL Ltd | AU:CSL | $59.87 Billion | AU$174.41 |
| #505 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $145.62 |
GlycoNex Historical Marketcap From 2015 to 2026
Between 2015 and today, GlycoNex's market cap moved from $188.67 Million to $ 75.16 Million, with a yearly change of -8.49%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | NT$75.16 Million | -16.31% |
| 2025 | NT$89.81 Million | +2.79% |
| 2024 | NT$87.37 Million | -15.80% |
| 2023 | NT$103.77 Million | -2.30% |
| 2022 | NT$106.21 Million | +2.87% |
| 2021 | NT$103.24 Million | +3.14% |
| 2020 | NT$100.10 Million | +41.03% |
| 2019 | NT$70.98 Million | -11.89% |
| 2018 | NT$80.56 Million | +1.09% |
| 2017 | NT$79.69 Million | -30.65% |
| 2016 | NT$114.91 Million | -39.09% |
| 2015 | NT$188.67 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 17th, 2026 the market cap of GlycoNex was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $75.16 Million USD |
| MoneyControl | $75.16 Million USD |
| MarketWatch | $75.16 Million USD |
| marketcap.company | $75.16 Million USD |
| Reuters | $75.16 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About GlycoNex
GlycoNex Incorporation engages in the development of cancer drugs using glycosphingolipid antigen and human monoclonal antibody technologies in Taiwan. The company's development pipeline for the treatment of solid tumors includes GNX102, a humanized monoclonal antibody, currently under phase 1 clinical stage; GNX201, an antibody drug currently under preclinical stage; GNX203, glycan-directed anti… Read more